Tumor necrosis factor
EmergingTNF-alpha is the direct target of an entire major biologic drug class (anti-TNF agents) across multiple autoimmune diseases.
TNF-alpha is a major inflammation-driving molecule, and blocking it directly is the basis of some of the most widely used biologic drugs in medicine today, used across several different autoimmune diseases. The molecule itself usually isn't measured directly — it's the target the drugs are built around.
Tumor necrosis factor alpha (TNF-α) is a central pro-inflammatory cytokine involved in immune signaling, inflammation, and cell death pathways, and one of the most therapeutically important cytokines in modern medicine.
TNF-α overactivity drives inflammation in rheumatoid arthritis, inflammatory bowel disease, psoriasis, and related autoimmune conditions; the cytokine itself isn't routinely measured to diagnose these conditions, but it's the direct drug target underlying an entire major biologic drug class.
TNF-α blood level isn't typically used as a diagnostic or monitoring test in routine clinical practice; diagnosis of TNF-driven autoimmune diseases relies on clinical criteria, imaging, and other specific serologic/inflammatory markers (like CRP, discussed earlier, and disease-specific antibodies).
Anti-TNF biologics (adalimumab, infliximab, etanercept, and others) are cornerstone treatments across rheumatoid arthritis, inflammatory bowel disease, and psoriasis, representing one of the most successful and widely used biologic drug classes in modern medicine.
One of the most therapeutically significant cytokines in modern medicine, despite not being routinely measured itself.
- General rheumatology and gastroenterology reference literature on anti-TNF biologic therapy across autoimmune disease.